Pharmaceutical industry – Page 55
-
Business
Bayer $145 million animal health deal
Move will strengthen anti-infective portfolio and introduce reproductive hormones
-
NewsOrphan drugs set for 'tremendous growth'
Drugs for rare diseases are rapidly becoming very profitable with growth predicted to outstrip non-orphan drugs
-
NewsChinese drug makers accused of using ‘gutter oil’
Oil reclaimed from drains may have been used to make an antibiotic intermediate
-
-
NewsDrug maker apologises for thalidomide tragedy
Fifty years after the event Grünenthal issues an apology as victims of the drug continue to press for compensation
-
Business
Myelofibrosis drug approved in EU
Jakavi (ruxolitinib) tablets are for the treatment of myelofibrosis, a rare disease affecting the bone marrow
-
Business
Alzheimer's drug flops in Phase III
Solanezumab from Eli Lilly missed the cognitive and functional primary endpoints of the trials
-
OpinionMonopoly money
Dean Baker says it’s time to start talking seriously about the way in which pharma is funded
-
OpinionProtecting patients at all costs
Suffering stagnant output, and beset by patent expiries and spiralling costs, drug discovery is in poor health. Simon Campbell prescribes a remedy
-
Business
Generic Actos approved
Mylan, Ranbaxy and Teva have won US marketing approval for their generic versions of Actos diabetes tablets
-
Business
Pfizer to pay $250m for Nexium
AstraZeneca has sold rights to an over the counter version of its heartburn tablets
-
Business
Elan spins off drug discovery
The new company will be called Neotope Biosciences and focus on chronic degenerative diseases
-
Business
DSM buys into cattle supplements
The company has struck a EUR465 million deal to acquire Tortuga
-
Business
Bapineuzunab dropped
Development for the Alzheimer’s treatment stopped after clinical tests
-
BusinessIrish pharma exports tumble
Seven of the top 10 drugs going off patent between 2011 and 2014 are produced in Ireland
-
Business
New cystic fibrosis drug in EU
Ivacaftor works by helping defective proteins function more normally
-
Business
Drugs top EU counterfeit imports
In 2011, medicines topped the list of fake products entering the EU
-
Business
GSK secures $3.6bn HGS deal
GlaxoSmithKline is set to buy Human Genome Sciences for $3.6 billion
-
BusinessObesity drug approved in US
Qsymia from Vivus joins Belviq in a lucrative part of the pharma industry